Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Mansour Assar

Interventional Cardiology Prescott, AZ Medical Doctor

NPI 1467459966 CMS profile 111241

3124 Willow Creek Rd Ste 200, Prescott, AZ 86301

Open in the dashboard

General payments

$8,428

291 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$95,654 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Mansour Assar of Prescott, AZ is reported in the CMS Open Payments database as having received $8,428 across 291 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $95,654 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 54th percentile of Interventional Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $907 44
2024 General $1,116 53
2023 General $742 37
2022 General $1,835 35
2021 General $439 25
2020 General $379 27
2019 General $3,009 70

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Mansour Assar
  • Interventional Cardiology median
  • Middle half of Interventional Cardiology
  • National median

In program year 2025, general payments to Mansour Assar were reported at $907. Among 6,173 Interventional Cardiology profiles paid that year, the median was $1,092 and the middle half received between $366 and $3,019.

Show as a table
Year Mansour Assar Interventional Cardiology median Middle half National median
2019 $3,009 $1,097 $329–$3,048 $163
2020 $379 $473 $161–$1,480 $114
2021 $439 $677 $233–$1,827 $132
2022 $1,835 $978 $333–$2,724 $149
2023 $742 $1,136 $382–$2,986 $160
2024 $1,116 $1,181 $395–$3,326 $164
2025 $907 $1,092 $366–$3,019 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Cardiovascular Systems Inc. $2,153 24 payments
  2. Medtronic, Inc. $1,694 26 payments
  3. Abiomed $833 87 payments
  4. Edwards Lifesciences Corporation $673 20 payments
  5. Novartis Pharmaceuticals Corporation $599 24 payments
  6. Abbott Laboratories $538 16 payments
  7. W. L. Gore & Associates, Inc. $341 17 payments
  8. Boston Scientific Corporation $331 18 payments
  9. Amgen Inc. $269 14 payments
  10. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $201 11 payments
  11. Other $797 34 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $5,120 282 payments
  2. Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program $2,000 1 payment
  3. Travel and Lodging $1,308 8 payments
Products named General payments · program years 2019–2025
  1. Peripheral Orbital Atherectomy System $2,101 18 payments
  2. Micra $1,331 14 payments
  3. Impella $811 85 payments
  4. LEQVIO $579 23 payments
  5. SAPIEN 3 Ultra RESILIA $434 16 payments
  6. Repatha $240 12 payments
  7. LifeVest $201 11 payments
  8. ENTRESTO $177 8 payments
  9. Edwards SAPIEN 3 Ultra Transcatheter Heart Valve $132 3 payments
  10. AMPLATZER Occluders $130 2 payments
  11. Other $2,378 122 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 43 drugs

Part D claims

3,245

Median for Interventional Cardiology: 2,236

Drug cost

$549,862

Median for Interventional Cardiology: $380,412

Branded share of claims

35.7%

Median for Interventional Cardiology: 27.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 177 $208,543
Entresto Sacubitril/Valsartan Brand 84 $117,598
Repatha Sureclick Evolocumab Brand 71 $61,114
Brilinta Ticagrelor Brand 45 $46,583
Xarelto Rivaroxaban Brand 17 $25,056
Jardiance Empagliflozin Brand 21 $23,796
Praluent Pen Alirocumab Brand 28 $18,902
Repatha Pushtronex Evolocumab Brand 20 $13,874
Clopidogrel Clopidogrel Bisulfate Brand 563 $6,678
Metoprolol Succinate Generic 371 $5,217

The 10 drugs with the highest cost, of 43 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 4,694 Part D prescribers listed as Interventional Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 121 billing codes

Paid by Medicare

$801,261

Of which drugs: $3,901

Medicare patients

757

Average age 77

Services billed

4,372

322 women, 435 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 75%
Arthritis 50%
Atrial fibrillation 38%
Chronic kidney disease 34%
Diabetes 31%
Heart failure 31%
COPD 21%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, regadenoson, 0.1 mg J2785 Office 154 620 $3,901

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

5 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
LEQVIO
  • Novartis Pharmaceuticals Corporation $262
$262 — —
Repatha
  • Amgen Inc. $112
$112 91 —
ENTRESTO
  • Novartis Pharmaceuticals Corporation $44
$44 84 —
Arcalyst
  • Kiniksa Pharmaceuticals International, plc $21
$21 — —
CAMZYOS
  • E.R. Squibb & Sons, L.L.C. $16
$16 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

291 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Cardiology in Arizona

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record